title: Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta.
abstract: We describe a study testing fibrillar beta-amyloid(1-42) (Abeta42) vaccination in dogs. Three young beagles (4.6 years) were immunized twice with Abeta42 and a Th1 adjuvant (TiterMax Gold). Animals generated primarily IgG2 and IgM antibody responses, which were specific for the Abeta(11-30) region of Abeta(1-42). Next, 3 aged beagles (8.9-13.8 years) were immunized 4 times with Abeta(42) and a Th2 adjuvant (Alum). We observed an acute increase in IgG2, a slower increase in IgG1 and Abeta antibodies of broader specificity (Abeta(1-15>) Abeta(11-30>) Abeta(6-20)). A nonsignificant increase in CSF Abeta(1-40) and decrease in Abeta(1-40/1-42) in cortex was detected. Canines may be a useful system for testing an Abeta vaccine.
authors.affiliation: Institute for Brain Aging & Dementia, Department of Neurology, University of California, 1259 Gillespie Neuroscience Research Facility, Irvine, CA 92697-4540, USA. ehead@uci.edu
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Head
authors.forename: Edward G
authors.initials: EG
authors.lastname: Barrett
authors.forename: M Paul
authors.initials: MP
authors.lastname: Murphy
authors.forename: Pritam
authors.initials: P
authors.lastname: Das
authors.forename: Mihaela
authors.initials: M
authors.lastname: Nistor
authors.forename: Floyd
authors.initials: F
authors.lastname: Sarsoza
authors.forename: Charles C
authors.initials: CC
authors.lastname: Glabe
authors.forename: Rakez
authors.initials: R
authors.lastname: Kayed
authors.forename: Saskia
authors.initials: S
authors.lastname: Milton
authors.forename: Vitaly
authors.initials: V
authors.lastname: Vasilevko
authors.forename: Norton W
authors.initials: NW
authors.lastname: Milgram
authors.forename: Michael G
authors.initials: MG
authors.lastname: Agadjanyan
authors.forename: David H
authors.initials: DH
authors.lastname: Cribbs
authors.forename: Carl W
authors.initials: CW
authors.lastname: Cotman
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000534:Alum Compounds / Q000008:administration & dosage; D000544:Alzheimer Disease / Q000276:immunology / Q000517:prevention & control*; D023582:Alzheimer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D016229:Amyloid beta-Peptides / Q000008:administration & dosage* / Q000134:cerebrospinal fluid / Q000276:immunology; D000818:Animals; D002540:Cerebral Cortex / Q000378:metabolism; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D018604:Epitope Mapping; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D008297:Male; D023421:Models, Animal; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000276:immunology; D011060:Poloxalene / Q000008:administration & dosage
chemical_list: D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); C086752:TiterMax; C041524:aluminum sulfate; D011060:Poloxalene